ZAP70
Top inhibitors
| Drug | Inhibition % | Gini |
|---|---|---|
| Futibatinib | 46.1 | 0.72 |
| Ruxolitinib | 11.7 | 0.59 |
| Canertinib | 11.2 | 0.67 |
| Vemurafenib | 10.5 | 0.60 |
| Mobocertinib | 9.5 | 0.76 |
| Repotrectinib | 9.5 | 0.61 |
| Crizotinib | 9.3 | 0.58 |
| Erdafitinib | 7.1 | 0.74 |
| Neratinib | 6.8 | 0.60 |
| Asciminib | 6.3 | 0.60 |
| Lenvatinib | 6.2 | 0.73 |
| Capmatinib | 6.0 | 0.58 |
| Upadacitinib | 5.8 | 0.66 |
| Regorafenib | 5.4 | 0.72 |
| Dacomitinib | 5.4 | 0.66 |
Known variants
Cancer associations
| Mutation | Cancer type | Organ | Source |
|---|---|---|---|
Y319F | chronic_lymphocytic_leukemia | Blood/Lymphatic System | https://depmap.org/portal. |